ReviewWorld journal of hepatology2014
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.
Review in World journal of hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- ACG Clinical Guideline: Primary Sclerosing Cholangitis.The American journal of gastroenterology · 2015Guideline
- The Significance of Enzymatic Cholestasis in Inflammatory Bowel Disease Patients for the Diagnosis of Primary Sclerosing Cholangitis-A Retrospective Study.Journal of clinical medicine · 2025Article
- Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- Dual Biologic Therapy Induces Remission in Refractory Crohn's Disease With Vedolizumab and Ustekinumab.Crohn's & colitis 360 · 2025Article
- The potential of volatile organic compounds to diagnose primary sclerosing cholangitis.JHEP reports : innovation in hepatology · 2024Article
- Choledochoscopy: An update.World journal of gastrointestinal endoscopy · 2021Review
- Liver involvement in inflammatory bowel disease: What should the clinician know?World journal of hepatology · 2021Review
- Adherence to Recommendations and Quality of Endoscopic Colorectal Cancer Surveillance in Long-Standing Ulcerative Colitis.Inflammatory intestinal diseases · 2021Article
- Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.The American journal of gastroenterology · 2020Review
- Hepatobiliary manifestations of inflammatory bowel disease in children.Clinical and experimental hepatology · 2019Review
- Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.Liver research (Beijing, China) · 2019Article
- Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study.BMC gastroenterology · 2019Article
- Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.World journal of gastroenterology · 2019Review
- Therapeutic effect of photodynamic therapy for nonresectable cholangiocarcinoma: Protocol for a meta-analysis and systematic review.Medicine · 2018Article
- Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.Gut and liver · 2018Review
- Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies.BMC surgery · 2017Article
- Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.BMC cancer · 2016Article
- Risk of Colorectal Cancer After Solid Organ Transplantation in the United States.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Article
- Controversies in the management of primary sclerosing cholangitis.World journal of hepatology · 2016Review
- Psoriasis and inflammatory bowel disease: links and risks.Psoriasis (Auckland, N.Z.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with primary sclerosing cholangitis (PSC) complicated by inflammatory bowel disease (IBD) represent a distinct subset of patients with unique characteristics, which have serious clinical implications. The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective. The prevalence of IBD, mainly ulcerative colitis in PSC patients is estimated to be 21%-80%, dependent on screening programs and nationality. PSC-associated colitis is likely to be extensive, characterized by rectal sparing, backwash ileitis, and generally mild symptoms. It is also more likely to progress to colorectal malignancy, making it imperative for clinicians to maintain a high level of suspicion when tackling PSC patients. There is no optimal surveillance strategy but current guidelines advocate that colonoscopy is necessary at the time of PSC diagnosis with annual endoscopic follow-up. Random biopsies have been criticized and a shift towards targeted biopsies using chromoendoscopy, laser endomicroscopy and narrow-band imaging has been noted. Techniques directed towards genetic mutations instead of histological abnormalities hold promise for easier, more accurate diagnosis of dysplastic lesions. Chemopreventive measures against colorectal cancer have been sought in these patients. Ursodeoxycholic acid seemed promising at first but subsequent studies yielded conflicting results showing anticarcinogenic effects in low doses (8-15 mg/kg per day) and carcinogenic properties in high doses (15-30 mg/kg per day).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.